U.S. Markets open in 2 hrs 8 mins

Achillion Pharmaceuticals (ACHN) Shares March Higher, Can It Continue?

Zacks Equity Research
Royal Bank of Scotland (RBS) plans to keep on adding new features to its digital bank in accordance to clients' demand and counter growing competition from other digital banks.

As of late, it has definitely been a great time to be an investor in Achillion Pharmaceuticals, Inc. ACHN. The stock has moved higher by 23.4% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.

We certainly think that this might be the case, particularly if you consider ACHN’s recent earnings estimate revision activity. From this look, the company’s future is quite favorable; as ACHN has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn’t the top for the in-focus company. You can see the complete list of today’s Zacks #1 Rank stocks here.

5 Companies Verge on Apple-Like Run

Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2018 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs. A bonus Zacks Special Report names this breakthrough and the 5 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains.

Click to see them right now >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Achillion Pharmaceuticals, Inc. (ACHN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research